MaxCyte Overview
- Founded
- 1998
- Status
- Public
- Employees
- 65
- Stock Symbol
- MXCT
- Share Price
- $3.13
- (As of Thursday Closing)
MaxCyte General Information
Description
MaxCyte Inc operates in the United States healthcare sector. It develops proprietary electroporation technology, which used blood cells instead of traditional chemical methods to transport medical gene therapies to targeted sites, increasing their safety and efficacy. The company technology finds its use in biotechnology and pharmaceutical firms engaged in cell therapy, including gene editing and immuno-oncology and in drug discovery, development, and biomanufacturing. Its products include MaxCyte STX, VLX, and GT. The company application includes Cell/Gene Therapy, Protein Production, Cell-based Assays, Gene Editing, Cell Line Development, and Viral Vectors/Vaccines. It acquires its income principally from the sale or lease of instruments and processing assemblies.
Contact Information
Website
Formerly Known As
TheraMed
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
LON
Primary Office
- 22 Firstfield Road
- Suite 110
- Gaithersburg, MD 20878
- United States
+1 (301) 000-0000
MaxCyte Timeline
MaxCyte Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.13 | $3.09 | $1.22 - $3.22 | $241M | 77.2M | 107K | -$0.23 |
MaxCyte Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 | FY 2017 31-Dec-2017 |
|---|---|---|---|---|
| EV | 179,038 | 79,149 | 109,399 | 139,640 |
| Revenue | 24,140 | 21,621 | 16,667 | 13,985 |
| EBITDA | (8,459) | (11,806) | (8,081) | (9,149) |
| Net Income | (9,487) | (12,895) | (8,869) | (9,917) |
| Total Assets | 53,377 | 29,985 | 24,268 | 31,398 |
| Total Debt | 6,973 | 7,211 | 5,056 | 5,030 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
MaxCyte Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore MaxCyte‘s full profile, request access.
Request a free trialMaxCyte Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is available in the PitchBook Platform. To explore MaxCyte‘s full profile, request access.
Request a free trialMaxCyte Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
MaxCyte Inc operates in the United States healthcare sector. It develops proprietary electroporation technology, which u
Drug Discovery
Gaithersburg, MD
65
As of 2019
000.00
000000000
000.00
0000000
t labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris
0000000000000
Menlo Park, CA
00
As of 0000
00000
000000&0
00000
00000000
velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
0000 000000000
Cambridge, United Kingdom
00
As of 0000
00.000
0000000000
00.000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialMaxCyte Competitors (28)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aravive Inc | Corporate Backed or Acquired | Menlo Park, CA | 00 | 00000 | 000000&0 | 00000 |
| 000000000 | Venture Capital-Backed | Cambridge, United Kingdom | 00 | 00.000 | 0000000000 | 00.000 |
| 0000000 0000000000 | Formerly VC-backed | Watertown, MA | 00 | 00000 | 000000000 - | 00000 |
| 000000000 00000000 | Corporation | Carlsbad, CA | 000000000 - | |||
| 00000 0000000000 | Formerly VC-backed | San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
MaxCyte Executive Team (14)
MaxCyte Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| Arthur Mandell | Self | Board Member | 000 0000 |
| Douglas Doerfler | MaxCyte | Chief Executive Officer & Board Member | 000 0000 |
| John Johnston | MaxCyte | Board Member | 000 0000 |
| J. Stark Thompson Ph.D | MaxCyte | Non-Executive Chairman | 000 0000 |
| Ronald Holtz | MaxCyte | Chief Accounting Officer, Accounting & Board Member | 000 0000 |
MaxCyte Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialMaxCyte Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore MaxCyte‘s full profile, request access.
Request a free trial